Canada markets closed

Atai Life Sciences N.V. (ATAI)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.1200+0.0800 (+7.69%)
At close: 04:00PM EST
1.1400 +0.02 (+1.79%)
After hours: 07:59PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close1.0400
Open1.0800
Bid1.1200 x 800
Ask1.1400 x 3100
Day's Range1.0250 - 1.1500
52 Week Range1.0250 - 3.6500
Volume1,067,906
Avg. Volume598,668
Market Cap185.931M
Beta (5Y Monthly)0.83
PE Ratio (TTM)N/A
EPS (TTM)-0.4300
Earnings DateNov 14, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.32
  • GlobeNewswire

    atai Life Sciences Reports Third Quarter 2023 Financial Results and Pipeline Highlights

    Phase 2b study of RL-007 in CIAS patients continues to be on track to report data in 2H 2024 and data from the EMP-01 (MDMA derivative) Phase 1 study is anticipated to report out later this year. Phase 1 data of VLS-01 (a proprietary oral transmucosal film formulation of DMT) demonstrated that 160mg of VLS-01 reached exposure levels comparable to 30mg of IV DMT. Acceptance of three non-clinical poster presentations at upcoming medical meetings, including non-clinical data for RL-007 and two nove

  • Market Exclusive

    Weekly Roundup on the Cannabis Sector & Psychedelic Sector

    Key Takeaways; Cannabis Sector Trulieve is challenging 280E cannabis taxation, seeking $143 million federal tax refund. TerrAscend raised its full year 2023 guidance, triggering a surge in stock price. Red White & Bloom won the race to acquire Aleafia Health after an earlier stumble. Key Takeaways; Psychedelic Sector Atai strengthened investment in IntelGenx technologies. Awakn’s […] The post Weekly Roundup on the Cannabis Sector & Psychedelic Sector appeared first on Market Exclusive.

  • CNW Group

    ATAI LIFE SCIENCES ANNOUNCES FILING OF EARLY WARNING REPORT

    This press release is being issued pursuant to National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting Issues ("NI 62-103"), in connection with certain transactions completed by atai Life Sciences AG (Nasdaq: ATAI) ("atai") and IntelGenx Technologies Corp. (the "IntelGenx"), that were previously described in a press release issued by IntelGenx on August 31 2023.